



Department of Health Care Finance



**PHARMACY & THERAPEUTICS
COMMITTEE MEETING**

Thursday, March 6th, 2025

Time: 2:30 PM – 5:30 PM

Online Only

***Please register at:**

https://primetherapeutics.zoom.us/webinar/register/WN_X6LR8YwxRgiYbn9t2sShOg.

- | | |
|--------------------------------------|---|
| 1) Call to Order | Charlene Fairfax, RPh |
| 2) Minutes of Previous Meeting | Charlene Fairfax, RPh |
| 3) Comments from Interested Parties* | Gidey Amare, RPh, MS |
| 4) Clinical Drug Class Reviews | Zakia Al-Amin, PharmD, BCACP, RPh
Ronald E. Kavanagh, BSpPharm, PharmD, PhD, RPh |

Androgenic Agents	Histamine-2-Receptor Antagonists
Antibiotics, Vaginal	Hyperparathyroidism Agents
Antiemetics/Antivertigo Agents	Hypoglycemics, Incretin Mimetics/Enhancers
Antihyperuricemics	Hypoglycemics, Insulins
Bladder Relaxants	Hypoglycemics, Meglitinides
Bone Resorption and Suppression Agents	Hypoglycemics, Metformins
BPH Agents	Hypoglycemics, SGLT2 Inhibitors
Colony Stimulating Factors	Hypoglycemics, Thiazolidinediones
Erythropoiesis Stimulating Agents	Pancreatic Enzymes
Fertility Agents	Phosphate Binders
GI Motility, IBS, Chronic	Progestins For Cachexia
Glucagon Agents	Proton Pump Inhibitors
Growth Hormone	Ulcerative Colitis Agents
H. Pylori Agents	Vaginal Estrogen Preparations

- | | |
|--|--|
| 5) Executive Session (Committee Only)** | Charlene Fairfax, RPh
MMA Representatives |
| 6) Final Recommendations of Preferred Drugs*** | MMA Representatives |
| 7) Announcement of Next Scheduled P&T Committee Meeting
Thursday, June 5 th , 2025 | Charlene Fairfax, RPh |
| 8) Final Comments and Adjournment | Charlene Fairfax, RPh |

***Individuals wishing to make oral presentations to the Committee will be limited to three (3) minutes only**
****Closed Session**
*****Open Session**